Burning Rock Biotech Ltd

BNR

Explore Our Financial Data > Companies > Burning Rock Biotech Ltd
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
BNR
CIK0001792267
SIC8071
SectorServices
Industry CategoryHealthcare
Industry GroupServices – Health

Contact

AddressNO. 5 XINGDAO RING ROAD NORTH,, INTERNATIONAL BIO ISLAND, GUANGZHOU, GUANGDONG, F4, 510005
Website brbiotech.com
Phone86 18501641666
CEOYu S. Han
Employees1,390

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$75.70 million
Pre-Tax Income$-91.73 million
Net Income$-92.07 million
Net Income to Common$-92.07 million
EPS$-1.80
View All
Balance Sheet
Cash$86.63 million
Assets$146.48 million
Liabilities$38.25 million
Common Equity$108.23 million
Liabilities & Equity$146.48 million
View All
Cash Flow Statement
Net Income$-92.07 million
Cash From Operating Activities$-36.03 million
Cash From Investing Activities$-1.31 million
Cash From Financing Activities$-6.88 million
Change in Cash$-43.67 million
View All
Calculations
NOPAT$-65.99 million
EBITDA$-75.47 million
Price to EarningsN/A
Price to Book$0.27
ROE-66.68%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2024. 2024 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitabil

Article Link

Burning Rock Announces Results of 2024 Annual General Meeting

GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Er

Article Link

Burning Rock Biotech’s Strategic Growth and Financial Results

Burning Rock Biotech (BNR) has released an update. Burning Rock Biotech reported a slight revenue increase to RMB128.6 million for Q3 2024, driven by a strong performance in in-hospital and pharma research services, despite a decline in central lab business. The company’s strategic moves include a partnership with MGI Tech and approval for a groundbreaking lung cancer diagnostic, which could bolster its market position. Notably, Burning Rock achieved a significant reduction in operating expenses

Article Link

Burning Rock Reports Third Quarter 2024 Financial Results

GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2024. Recent Business Updates Therapy Selection Presented study results at the 2024 World Conference on Lung Cancer in September 2024. “Neoadjuvant sintilimab plus chemotherapy

Article Link

Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024

GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 31, 2024 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. Th

Article Link